5 Stocks Improving Performance Of The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 53 points (-0.3%) at 16,478 as of Wednesday, Jan. 8, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,242 issues advancing vs. 1,672 declining with 178 unchanged.

The Health Care sector currently sits up 0.9% versus the S&P 500, which is unchanged. Top gainers within the sector include Forest Laboratories ( FRX), up 15.6%, Incyte ( INCY), up 5.8%, Alkermes ( ALKS), up 5.7%, Jazz Pharmaceuticals ( JAZZ), up 5.7% and Endo Health Solutions ( ENDP), up 5.4%. A company within the sector that fell today was Humana ( HUM), up 1.4%.

TheStreet would like to highlight 5 stocks pushing the sector higher today:

5. Express Scripts ( ESRX) is one of the companies pushing the Health Care sector higher today. As of noon trading, Express Scripts is up $0.55 (0.8%) to $70.39 on average volume. Thus far, 1.8 million shares of Express Scripts exchanged hands as compared to its average daily volume of 4.6 million shares. The stock has ranged in price between $69.61-$70.40 after having opened the day at $70.07 as compared to the previous trading day's close of $69.84.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $56.3 billion and is part of the health services industry. The company has a P/E ratio of 30.2, above the S&P 500 P/E ratio of 17.7. Shares are down 0.6% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Express Scripts Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Biogen Idec ( BIIB) is up $11.47 (4.2%) to $284.99 on average volume. Thus far, 512,992 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $274.25-$285.55 after having opened the day at $276.64 as compared to the previous trading day's close of $273.52.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $65.0 billion and is part of the drugs industry. The company has a P/E ratio of 38.6, above the S&P 500 P/E ratio of 17.7. Shares are down 2.2% year to date as of the close of trading on Tuesday. Currently there are 13 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.51 (1.0%) to $53.07 on light volume. Thus far, 1.9 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 7.1 million shares. The stock has ranged in price between $52.30-$53.44 after having opened the day at $52.48 as compared to the previous trading day's close of $52.56.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $86.7 billion and is part of the drugs industry. The company has a P/E ratio of 31.7, above the S&P 500 P/E ratio of 17.7. Shares are down 1.1% year to date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, solid stock price performance, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bristol-Myers Squibb Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Celgene Corporation ( CELG) is up $2.80 (1.7%) to $167.41 on average volume. Thus far, 1.1 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $164.04-$167.91 after having opened the day at $164.90 as compared to the previous trading day's close of $164.61.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $67.0 billion and is part of the drugs industry. The company has a P/E ratio of 46.7, above the S&P 500 P/E ratio of 17.7. Shares are down 2.6% year to date as of the close of trading on Tuesday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $1.22 (1.7%) to $74.00 on average volume. Thus far, 4.6 million shares of Gilead exchanged hands as compared to its average daily volume of 10.4 million shares. The stock has ranged in price between $72.53-$74.17 after having opened the day at $73.17 as compared to the previous trading day's close of $72.78.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $112.3 billion and is part of the drugs industry. The company has a P/E ratio of 40.2, above the S&P 500 P/E ratio of 17.7. Shares are down 3.1% year to date as of the close of trading on Tuesday. Currently there are 16 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

Comcast's Brian Roberts vs. Disney's Bob Iger: Which Titan Will Nab Fox?

Comcast's Brian Roberts vs. Disney's Bob Iger: Which Titan Will Nab Fox?